We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.77B
1-Year Est. Return
307.72%
This Fund
S&P 500
This Quarter
Est. Return
+49.42%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$620M
AUM Growth
+$109M
(+21%)
Cap. Flow
-$29M
Cap. Flow
% of AUM
-4.68%
Top 10 Holdings %
Top 10 Hldgs %
99.25%
Holding
17
New
5
Increased
3
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$145M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$32.2M |
| 3 |
Beam Therapeutics
BEAM
|
+$10.1M |
| 4 |
EPIX
ESSA Pharma
EPIX
|
+$6.06M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$5.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$100M |
| 2 |
Fate Therapeutics
FATE
|
+$83.3M |
| 3 |
Relay Therapeutics
RLAY
|
+$21.8M |
| 4 |
Arvinas
ARVN
|
+$9.29M |
| 5 |
MacroGenics
MGNX
|
+$9.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Intellia Therapeutics
NTLA
$1.59B
| $301M | 48.58% |
+1,859,926
| New | +$145M |
|
|
XLRN
2
DELISTED
Acceleron Pharma
XLRN
| $221M | 35.63% |
1,760,346
+255,334
| +17% | +$32.2M |
|
|
3
Fate Therapeutics
FATE
$324M
| $29.2M | 4.7% |
335,918
-1,034,215
| -75% | -$83.3M |
|
|
4
BridgeBio Pharma
BBIO
$15.9B
| $20.5M | 3.31% |
336,817
-1,753,332
| -84% | -$100M |
|
|
5
Beam Therapeutics
BEAM
$2.83B
| $16.3M | 2.64% |
+126,985
| New | +$10.1M |
|
|
VERV
6
DELISTED
Verve Therapeutics
VERV
| $6.21M | 1% |
+103,013
| New | +$4.28M |
|
|
INBX
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.21M | 1% |
225,480
+175,771
| +354% | +$3.66M |
|
|
EPIX
8
DELISTED
ESSA Pharma
EPIX
| $5.96M | 0.96% |
+208,524
| New | +$6.06M |
|
9
Keros Therapeutics
KROS
$211M
| $4.42M | 0.71% |
104,186
+17,299
| +20% | +$937K |
|
|
10
Aclaris Therapeutics
ACRS
$793M
| $4.39M | 0.71% |
+250,000
| New | +$5.68M |
|
|
11
Relay Therapeutics
RLAY
$4.34B
| $4.38M | 0.71% |
119,775
-662,696
| -85% | -$21.8M |
|
|
GBIO
12
DELISTED
Generation Bio
GBIO
| $289K | 0.05% |
1,074
-20,862
| -95% | -$6.24M |
|
|
13
Arvinas
ARVN
$517M
| – | – |
-140,511
| Closed | -$9.29M |
|
14
C4 Therapeutics
CCCC
$408M
| – | – |
-140,034
| Closed | -$5.18M |
|
15
Fulcrum Therapeutics
FULC
$243M
| – | – |
-49,868
| Closed | -$587K |
|
16
Immunovant
IMVT
$8.27B
| – | – |
-65,849
| Closed | -$1.06M |
|
|
17
MacroGenics
MGNX
$285M
| – | – |
-286,195
| Closed | -$9.12M |
|
Similar funds
VVP
ABC
SCA
ACH
GL
VA
GCC
SB
Darwin Global Management's Q2 2021 Portfolio in Review
As of Q2 2021, Darwin Global Management held 17 positions worth $620M, up 21% from $511M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Darwin Global Management withdrew a net $29M in Q2 2021, closing 5 positions and reducing 4 holdings. Its most notable exit was Arvinas, an estimated $9.29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Darwin Global Management opened a new position in Intellia Therapeutics worth $301M.
- Darwin Global Management's largest Q2 2021 buy was Intellia Therapeutics: 1,859,926 shares worth $301M.
- Darwin Global Management added most to Acceleron Pharma in Q2 2021, an estimated $32.2M increase.
- Darwin Global Management's biggest Q2 2021 reduction was BridgeBio Pharma, cutting an estimated $100M.
- Darwin Global Management fully exited Arvinas in Q2 2021, selling an estimated $9.29M.
- Darwin Global Management's ten largest holdings make up 99% of its $620M portfolio in Q2 2021.
- Darwin Global Management opened 5 new positions and closed 5 in Q2 2021.
- Darwin Global Management's portfolio value rose 21% quarter-over-quarter to $620M.
Based on Darwin Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.